Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Feb, 2015 | Pages:
68 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Pemphigus - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Pemphigus - Pipeline Review, H1 2015', provides an overview of the Pemphigus's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Pemphigus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pemphigus and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Pemphigus - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Pemphigus and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Pemphigus products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Pemphigus pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reason to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Pemphigus - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Pemphigus pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Pemphigus Overview 7 Therapeutics Development 8 Pipeline Products for Pemphigus - Overview 8 Pipeline Products for Pemphigus - Comparative Analysis 9 Pemphigus - Therapeutics under Development by Companies 10 Pemphigus - Therapeutics under Investigation by Universities/Institutes 11 Pemphigus - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Unknown Stage Products 15 Pemphigus - Products under Development by Companies 16 Pemphigus - Products under Investigation by Universities/Institutes 17 Pemphigus - Companies Involved in Therapeutics Development 18 Clinuvel Pharmaceuticals Limited 18 Genmab A/S 19 HanAll Biopharma Co., Ltd. 20 Immunomedics, Inc. 21 Momenta Pharmaceuticals, Inc. 22 Novartis AG 23 PinCell srl 24 Pemphigus - Therapeutics Assessment 25 Assessment by Monotherapy Products 25 Assessment by Target 26 Assessment by Mechanism of Action 28 Assessment by Route of Administration 30 Assessment by Molecule Type 32 Drug Profiles 34 afamelanotide - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Antibody for Autoimmune Disorders and Inflammation - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 DP-C006 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Drugs to Target HSP27 for Autoimmune Disorders - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 HL-161 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 ofatumumab - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 PC-111 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 VAY-736 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 veltuzumab - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Pemphigus - Recent Pipeline Updates 51 Pemphigus - Dormant Projects 60 Pemphigus - Product Development Milestones 61 Featured News & Press Releases 61 Nov 21, 2014: Immunomedics Announces Orphan Drug Designation for Veltuzumab for the Treatment of Pemphigus 61 Oct 07, 2014: Stiefel, a GSK company, announces start of phase III study of subcutaneous ofatumumab for pemphigus vulgaris 61 May 22, 2014: Scenesse receives US orphan-drug designation in Hailey-Hailey Disease 62 May 19, 2014: Afamelanotide 16mg recognised for potential to treat rare Hailey-Hailey Disease 63 Feb 10, 2014: Phase II study of SCENESSE in rare skin disorder Hailey-Hailey Disease commences 63 Oct 28, 2013: Positive pilot data published on SCENESSE in rare skin disorder 64 Jul 04, 2013: Genmab Collaborator GSK Starts New Ofatumumab Phase III Study in Rare Skin Disorder 65 Appendix 67 Methodology 67 Coverage 67 Secondary Research 67 Primary Research 67 Expert Panel Validation 67 Contact Us 67 Disclaimer 68
List of Tables Number of Products under Development for Pemphigus, H1 2015 8 Number of Products under Development for Pemphigus - Comparative Analysis, H1 2015 9 Number of Products under Development by Companies, H1 2015 10 Number of Products under Investigation by Universities/Institutes, H1 2015 11 Comparative Analysis by Late Stage Development, H1 2015 12 Comparative Analysis by Clinical Stage Development, H1 2015 13 Comparative Analysis by Early Stage Development, H1 2015 14 Comparative Analysis by Unknown Stage Development, H1 2015 15 Products under Development by Companies, H1 2015 16 Products under Investigation by Universities/Institutes, H1 2015 17 Pemphigus - Pipeline by Clinuvel Pharmaceuticals Limited, H1 2015 18 Pemphigus - Pipeline by Genmab A/S, H1 2015 19 Pemphigus - Pipeline by HanAll Biopharma Co., Ltd., H1 2015 20 Pemphigus - Pipeline by Immunomedics, Inc., H1 2015 21 Pemphigus - Pipeline by Momenta Pharmaceuticals, Inc., H1 2015 22 Pemphigus - Pipeline by Novartis AG, H1 2015 23 Pemphigus - Pipeline by PinCell srl, H1 2015 24 Assessment by Monotherapy Products, H1 2015 25 Number of Products by Stage and Target, H1 2015 27 Number of Products by Stage and Mechanism of Action, H1 2015 29 Number of Products by Stage and Route of Administration, H1 2015 31 Number of Products by Stage and Molecule Type, H1 2015 33 Pemphigus Therapeutics - Recent Pipeline Updates, H1 2015 51 Pemphigus - Dormant Projects, H1 2015 60
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
